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Summary
 
Interleukin (IL)-4–deficient mice were used to assess susceptibility to systemic or gastrointesti-
nal 
 
Candida albicans
 
 infections, as well as parameters of innate and elicited T helper immunity.
In the early stage of systemic infection with virulent 
 
C. albicans
 
, an unopposed interferon
(IFN)-
 
g
 
 response renders IL-4–deficient mice more resistant than wild-type mice to infection.
Yet, IL-4–deficient mice failed to efficiently control infection in the late stage and succumbed
to it. Defective IFN-
 
g
 
 and IL-12 production, but not IL-12 responsiveness, was observed in
IL-4–deficient mice that failed to mount protective T helper type 1 cell (Th1)-mediated ac-
quired immunity in response to a live vaccine strain of the yeast or upon mucosal immuniza-
tion in vivo. In vitro, IL-4 primed neutrophils for cytokine release, including IL-12. However,
late treatment with exogenous IL-4, while improving the outcome of infection, potentiated
CD4
 
1
 
 Th1 responses even in the absence of neutrophils. These findings indicate that endoge-
nous IL-4 is required for the induction of CD4
 
1
 
 Th1 protective antifungal responses, possibly
through the combined activity on cells of the innate and adaptive immune systems.
 
T
 
helper cells play a central role in regulating immune
responses to the fungus 
 
Candida albicans
 
 by secreting
cytokines that modulate the development and activity of
immune effectors. The dominance of either one of the two
Th subsets (Th1 and Th2) directly correlates with the out-
come and severity of infection (1, 2). In experimental
models of candidiasis, protection correlates with the occur-
rence of Th1 responses (3–5), whereas Th2 responses are
associated with disease exacerbation and pathology (6–8). A
variety of factors control CD4
 
1
 
 Th subset development
and regulation in murine candidiasis (1, 2). Cytokines are
among these, acting not only as modulators of antifungal
effector functions but also as key regulators in the develop-
ment of the different Th subsets from precursor Ths. Early
in infection, neutralization of Th1 cytokines (IFN-
 
g
 
 and
IL-12; references 6, 9–11) and administration of Th2 cy-
tokines (IL-4 or IL-10; reference 12) lead to the onset of
Th2 rather than Th1 responses, whereas Th2 cytokine
neutralization allows the development of Th1 rather than
Th2 responses (4, 5, 8).
The finding that IL-4 fails to convert an already estab-
lished Th1 response into a Th2 response (12) and that it is
indeed required for the expression of protective immunity
in mice with candidiasis (13), suggests complex levels of cy-
tokine-mediated regulation of Th development and effec-
tor function, which were previously unappreciated. In par-
ticular, recent studies in IL-4–deficient mice have revealed
important novel roles for IL-4, which would not have been
predicted from data on IL-4 neutralization in vivo (14–16).
Thus, in genetically susceptible IL-4–deficient mice with
toxoplasmosis, IL-4 appears to have different roles, depend-
ing on the phase of infection (16). The infection is also ex-
acerbated in genetically resistant IL-4–deficient mice, IL-4
being required for protection in the late stage of infection
(15). The protective effect of IL-4 appears to be due to its
ability to sustain IFN-
 
g
 
 production by activated CD4
 
1
 
 T
cells (15), a finding that, although previously described (17,
18), is not easy to accommodate in the paradigm of CD4
 
1
 
Th regulation by IL-4 (19). However, recent lineage abla-
tion studies by Flavell et al. provide convincing evidence
on the requirement of IL-4 in the differentiation of both
Th2 and Th1 effector cells from precursor CD4
 
1
 
 Ths
(20–22).
In this study, we assessed susceptibility and parameters of
innate and adaptive Th immunity in IL-4–deficient mice
infected with 
 
C. albicans.
 
 The results show the ability of
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these mice to successfully control the infection in the early
stage but not the late, IL-4 being required for induction of
protective CD4
 
1
 
 Th1 anticandidal responses.
 
Materials and Methods
 
Mice.
 
Breeding pairs of homozygous IL-4–deficient (IL-4
 
2
 
/
 
2
 
)
and control (IL-4
 
1
 
/
 
1
 
) BALB/c mice (23) were bred under spe-
cific, pathogen-free conditions. Mice of both sexes, 8–10 wk old,
were used. Procedures involving animals and their care were con-
ducted in conformity with national and international laws and
policies.
 
Yeasts, Infections, In Vivo Analyses, and Treatments.
 
The origin
and characteristics of the 
 
C. albicans
 
 highly virulent CA-6 strain
and the live vaccine strain PCA-2 used in this study have already
been described in detail (4–13). For infection, cells were washed
twice in saline, and diluted to the desired density to be injected
intravenously via the lateral tail vein in a volume of 0.5 ml/mouse
or intragastrically via an 18-gauge 4-cm-long plastic catheter, as
described (24). The viability of the cells was 
 
.
 
95% by trypan blue
exclusion and quantitative cultures. Quantification of yeast cells
in organs of infected mice (6–8/group) was performed by a plate-
dilution method, using Sabouraud dextrose agar, and results
(mean 
 
6
 
 SEM) were expressed as CFU per organ. Resistance to
reinfection was assessed by injecting mice with 10
 
6
 
 CA-6 cells in-
travenously, 14 d after primary infection. Mice succumbing to
yeast challenge were routinely necropsied for histopathological
confirmation of disseminated candidiasis. Recombinant murine
IL-4 (provided by Dr. Robert Coffman, DNAX Research Insti-
tute, Palo Alto, CA) was given intraperitoneally together with the
anti–IL-4 mAb 11B11 hybridoma (American Type Culture Col-
lection, Rockville, MD; 3 
 
m
 
g IL-4 
 
1
 
 30 
 
m
 
g mAb, each injection)
as described (12, 13). Anti–IL-4 mAb was injected intraperitoneally
at the dose of 0.5 mg affinity-purified mAb/injection, as de-
scribed (4, 13). Control groups were injected with saline or iso-
type-matched Ab (Zymed Laboratories, Inc., South San Fran-
cisco, CA). Both treatments were performed on days 6, 8, 10, and
12 after 
 
C. albicans
 
 infection. Long-lasting neutrophil depletion
was obtained as described (25), by administering RB6-8C5 (anti-
Ly6G) mAb intraperitoneally at the dose of 100 
 
m
 
g/mouse 2 d
before reinfection. Endotoxin was removed from all solutions
with Detoxi-gel (Pierce Chemical Co., Rockford, IL).
 
Purification and Culture of Cells.
 
CD4
 
1
 
 T lymphocytes were posi-
tively selected from pools of spleen cells by means of a panning
procedure using purified anti–murine CD4 mAb (GK1.5 hybri-
doma from American Type Culture Collection), which resulted
in a 
 
.
 
90% pure population on flow cytometric analysis (3–5).
CD4
 
1
 
 cells (5 
 
3
 
 10
 
6
 
) were cultured in the presence of 5 
 
3
 
 10
 
5
 
accessory macrophages and 5 
 
3
 
 10
 
5
 
 heat-inactivated yeast cells.
Unfractionated splenocytes (5 
 
3
 
 10
 
6
 
/ml) were cultured in the
presence of 10 
 
m
 
g/ml of Concanavalin A (Sigma Chemical Co.,
St. Louis, MO). Cultures of purified peritoneal neutrophils and
macrophages, collected 18 or 72 h, respectively, after intraperito-
neal inoculation of aged, endotoxin-free 10% thioglycollate solu-
tion (Difco, Detroit, MI), were done as described (25, 26) by in-
cubating 5 
 
3
 
 10
 
5
 
 cells in the presence of IFN-
 
g
 
 (400 U/ml) and
LPS (40 ng/ml, Sigma Chemical Co.) or 5 
 
3
 
 10
 
4
 
 
 
C. albicans
 
,
PCA-2. In some experiments, cells were exposed in vitro to rIL-4
(250 U/ml) for 8 h before addition of stimuli. Cytokine measure-
ment was performed in supernatants collected after 48 h (for lym-
phocytes) and 24 h (for neutrophils and macrophages).
 
Cytokine Assays.
 
The levels of IFN-
 
g
 
, IL-2, IL-4, IL-6, and
IL-10 were determined by means of cytokine-specific ELISA, us-
ing pairs of anticytokine mAbs, as described (3–13, 25, 26). The
Ab pairs used were as follows, listed by capture/biotinylated de-
tection: IFN-
 
g
 
, R4-6A2/XMG1.2; IL-2, JES6-1A12/JE5H4; IL-4,
BVD4-1D11/BVD6-24G2; IL-6, MP5-20F3/MP5-32c11; IL-10,
JES5-2A5/SXC-1 (PharMingen, San Diego, CA). For IL-12p70
measurement, a modified Ab-capture bioassay was used, as de-
scribed (7). Cytokine titers were calculated by reference to stan-
dard curves constructed with known amounts of recombinant cy-
tokines (from PharMingen, except IL-12, from Genetics Institute,
Boston, MA).
 
Candidacidal Assay and Nitrite Determination.
 
For the candidacidal
assay, 5 
 
3
 
 10
 
5
 
 splenic macrophages (obtained by 2-h plastic ad-
herence, 
 
.
 
95% pure on esterase staining) or elicited peritoneal
neutrophils were plated (0.1 ml/well) in 96-well flat-bottomed
microtiter plates (Costar, Cambridge, MA) and incubated with
10
 
5
 
 PCA-2 cells for 4 or 1 h, respectively, as described (27). Tri-
ton X-100 (final concentration: 0.1%) was then added to the
wells, and serial dilutions from each well were made in distilled
water. Pour plates (four to six replicate samples) were made by
spreading each sample on Sabouraud glucose agar. The number
of CFU was determined after incubation at 37
 
8
 
C and the per-
centage of CFU inhibition (means 
 
6
 
 SE) was determined as fol-
lows: percentage of colony formation inhibition 
 
5
 
 100 
 
2
 
 (CFU
experimental group/CFU control cultures) 
 
3
 
 100. Control cul-
tures consisted of 
 
C. albicans
 
 cells incubated without effector cells.
Nitrite concentration, a measure of nitric oxide (NO)
 
1
 
 synthesis,
was assayed in culture supernatants by a standard Griess reaction
adapted to microplates, as described (8). The Griess reagent was
prepared by mixing equal volumes of sulfanilamide (1.5% in 1 N
HCl) and naphthylethylene diamine dihydrochloride (0.15% in
H
 
2
 
O) (Sigma Chemical Co.). A volume of 100 
 
m
 
l of reagent was
mixed with 100 
 
m
 
l of supernatant and incubated for 30 min in
the dark. Absorbance of the chromophore formed was measured
at 540 nm in an automated microplate reader. The data represent
the means 
 
6
 
 SE of quadruplicate determinations and are ex-
pressed as 
 
m
 
g NO
 
2
 
2
 
/ml.
 
RNA Preparation and Reverse Transcriptase PCR.
 
Splenic mac-
rophages, peritoneal neutrophils, and CD4
 
1
 
 splenocytes were
subjected to RNA extraction by the guanidium thiocyanate-phe-
nol-chloroform procedure, as described (28). In brief, 3 
 
m
 
g of to-
tal RNA was incubated with 0.5 
 
m
 
g of oligo(dT) (Pharmacia
Biotech AB, Uppsala, Sweden) for 3 min at 65
 
8
 
C and chilled on
ice for 5 min. Each sample was then incubated for 2 h at 42
 
8
 
C af-
ter adding 20 U RNase inhibitors (Boehringer Mannheim, Mi-
lan, Italy), 1.5 mM deoxynucleoside triphosphates, 25 U avian
myeloblastosis virus reverse transcriptase (RT) (Boehringer Mann-
heim), and RT buffer (50 mM Tris-HCl, pH 8.3, 8 mM MgCl
 
2
 
,
30 mM KCl, and 10 mM dithiothreitol, final concentrations) in a
final volume of 20 
 
m
 
l. cDNA was diluted to a total volume of
500 
 
m
 
l with TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)
and frozen at 
 
2
 
20
 
8
 
C until use. Amplification of synthesized
cDNA from each sample was carried out as described previously
(29). In brief, 5 
 
m
 
l of cDNA was added to a reaction mixture
containing 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 3.0 mM
MgCl
 
2
 
, 0.01% gelatin, 0.2 mM deoxynucleoside triphosphates, 1
 
m
 
M of each primer, and 2.5 U AmpliTaq polymerase (Perkin-
Elmer Corp., Hayward, CA). Each 100-
 
m
 
l sample was overlaid
with 75 
 
m
 
l mineral oil (Sigma Chemical Co.) and incubated in a
 
1
 
Abbreviations used in this paper:
 
 HPRT, hypoxanthine-guanine phosphori-
bosyl transferase; mRNA, messenger RNA: MST, median survival time;
NO, nitric oxide; RT, reverse transcriptase. 
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DNA Thermal Cycler 480 (Perkin-Elmer Corp.) for a total of
30–35 cycles for each cytokine. For hypoxanthine-guanine phos-
phoribosyl transferase (HPRT) and IL-12, the primers, positive
controls, cycles, and temperature were as described elsewhere (9,
10). For IL-12R
 
b
 
1, IL-12R
 
b
 
2, and IL-4R, the primers were
synthesized using a 391 DNA synthesizer (PCR-MATE; Applied
Biosystems, Foster City, CA). The sequences of 5
 
9
 
 sense primers
and 3
 
9
 
 antisense primers for IL-12R
 
b
 
1 and IL-12R
 
b
 
2 were as
follows: IL-12
 
b
 
1, 5
 
9
 
- GAA CCA CAC ACA CTG TAC CCT
G, 3
 
9
 
- TTT AGT GGG TGG CAC GAG CC; IL-12
 
b
 
2, 5
 
9-
CAA GAC ATC GAC TAT GAC AGA C, 39- CAG GTT
GTG CTG TCG AGT CTC G. For IL-12Rb1 and b2, each cy-
cle consisted of 1 min at 948C, 1 min at 608C, and 1 min at 728C.
The positive controls were obtained through the courtesy of Dr.
Giorgio Trinchieri (Wistar Institute, Philadelphia, PA). For IL-
4R, the sequences of 59 sense primers and 39 antisense primers
were as follows: 59- TGT GAC CTA CAA GGA ACC CA, 39-
GCA AAA CAA CGG GAT GCA GA. For IL-4R, each cycle
consisted of 1 min at 948C, 1 min at 608C, and 1 min at 728C.
The HPRT primers were used as a control for both reverse tran-
scription and the PCR reaction itself, and also for comparing the
amount of products from samples obtained with the same primer.
The PCR fragments were analyzed by 1.5% agarose gel electro-
phoresis and visualized by ethidium bromide staining. PCR-assisted
messenger RNA (mRNA) amplification was repeated at least
twice for at least two separately prepared cDNA samples for each
experiment. Data are representative of at least three different ex-
periments.
Competitive RT-PCR. The semiquantitative competitive PCR
developed by Reiner et al. (30), was performed using the compet-
itor construct containing sequences for multiple cytokines, the prim-
ers for HPRT and IFN-g, and the PCR conditions described by
the authors. In brief, aliquots of cDNA were assayed for levels of
HPRT by placing serial dilutions from 1:1 to 1:40 of the experi-
mental cDNA against a fixed concentration of the competitor
construct and examining the ratio of competitor/wild-type band
intensity after amplification with HPRT-specific primers. Adjust-
ments were made in the amount of cDNAs needed to standardize
the HPRT levels to comparable levels among all groups. Serial
dilutions of these adjusted volumes of cDNA were then used to
quantitate cytokine levels using a fixed concentration of competi-
tor (3 and 1.5 pg/ml for HPRT and IFN-g, respectively) in each
reaction in the presence of cytokine-specific primers. The PCR
products were separated by electrophoresis in 2% agarose gels
containing ethidium bromide. The point of equivalence in inten-
sity between the competitor (upper band) and the cDNA (lower
band) indicates the relative concentration of mRNA.
Statistical Analysis. Survival and organ clearance data from
each group of wild-type mice were compared with those from
IL-4–deficient mice using the Mann-Whitney U test; P , 0.05
was considered significant. Student’s t test was used to determine
statistical significance between cytokine production of the two
groups. In vivo groups consisted of four to six animals. The data
reported are pooled from three experiments.
Results
IL-42/2 Mice Successfully Control C. albicans Infection in the
Early Stage, but Succumb to Infection in the Late Stage. IL-42/2
and IL-41/1 mice were injected intravenously with differ-
ent doses (106, 5 3 105 and 2 3 105) of highly virulent
CA-6, with 106 cells of the live vaccine strain PCA-2, or
intragastrically with 108 CA-6. Mice were monitored for
resistance to primary and secondary infections (Table 1)
and for fungal growth in the organs (Fig. 1). The results
show that, although the median survival time (MST) of
mice injected with the highest inoculum of CA-6 did not
differ between the two types of mice, IL-4–deficient mice
were more resistant than IL-41/1 to the lower inocula of
the yeast, as observed by the increased survival. IL-42/2
mice were as resistant as wild-type mice to infection with
PCA-2 or to intragastric infection with CA-6. However,
Table 1. Susceptibility of IL-42/2 and IL-41/1 Mice to C. albicans Infection
Mice
Primary infection Secondary infection*
Yeast Dose Route MST D/T Yeast Dose Route MST D/T
IL-42/2 CA-6 106 i.v. 4 8/8 – – – – –
CA-6 5 3 105 i.v. 16† 8/8 – – – – –
CA-6 2 3 105 i.v. .60† 0/8 CA-6 106 i.v. 5.5 4/4
CA-6 108 i.g. .60 0/8 CA-6 5 3 105 i.v. 10 4/4
PCA-2 106 i.v. .60 0/12 CA-6 106 i.v. 6 6/6
IL-41/1 CA-6 106 i.v. 5 12/12 – – – – –
CA-6 5 3 105 i.v. 7 8/8 – – – – –
CA-6 2 3 105 i.v. 15 8/8 – – – – –
CA-6 108 i.g. .60 0/12 CA-6 5 3 105 i.v. 21 6/6
PCA-2 106 i.v. .60 0/12 CA-6 106 i.v. .60 0/6
i.g., intragastric; MST, median survival time (d); D/T, dead animals over total mice infected.
*Surviving mice were reinfected 14 d after the primary challenge.
†P , 0.05, Mann Whitney U test (IL-42/2 versus IL-41/1).310 Anticandidal Th Responses in IL-42/2 Mice
on assaying the susceptibility of survivors to a subsequent
lethal CA-6 challenge, IL-41/1 mice either survived or
showed a remarkable resistance to reinfection, whereas
IL-4–deficient mice did not.
Quantification of yeast cells recovered from infected
mice revealed that the number of C. albicans cells decreased
in the kidneys of IL-42/2 mice throughout the first week
of infection with either 5 3 105 or 2 3 105 CA-6 cells.
However, at 14 d after infection, when no yeast cells were
recovered in mice surviving the lowest inoculum, an ex-
tensive fungal growth was observed in the kidneys of mice
succumbing to infection. In contrast, the fungal load in the
kidneys of wild-type mice was always higher and increased
continuously until death. In mice with gastrointestinal in-
fection, the number of yeast cells recovered from the stom-
ach was significantly lower in IL-42/2 than in IL-41/1
mice, even though both types of mice eventually survived
the infection. Resistance to CA-6 intravenous reinfection
was lower in IL-42/2 than IL-41/1 mice, as revealed by the
high number of yeast cells recovered from the kidneys of
IL-42/2 reinfected mice. Histopathological examination of
the kidneys of systemically infected IL-4–deficient mice re-
vealed patterns of lesions similar to those observed in resis-
tant or susceptible strains of mice infected intravenously (3–
5), with signs of extensive fungal growth and numerous
foci of inflammatory reaction (mainly consisting of poly-
morphonuclear cells) throughout the kidney parenchyma
of mice succumbing to infection and absence of pathologi-
cal lesions and fungal growth in kidneys of mice resistant to
infection (data not shown). Therefore, these data clearly
show a two-stage control of C. albicans infection in mice.
IL-4–deficient mice were highly resistant in the early stage
of infection, but highly susceptible in the late stage.
Early Control of C. albicans Infection in IL-42/2 Mice Is As-
sociated with Unimpaired Antifungal Activity of Phagocytic Cells.
To evaluate the contribution of cells of the innate immune
system on the ability of IL-4–deficient mice to efficiently
oppose infectivity in the early stage of infection, the anti-
fungal effector functions of macrophages and neutrophils
were assessed. Splenic macrophages and peritoneal neutro-
phils were obtained from IL-42/2 and 1/1 mice at 3 d after
intravenous infection with 5 3 105 CA-6 cells and assessed
for candidacidal activity and production of NO. The results
(Table 2) showed that the candidacidal activity of both
types of cells was severely depressed in IL-41/1 mice upon
infection, as opposed to the unimpaired activity of those
Figure 1. Fungal growth in the organs of IL-42/2 and IL-41/1 mice in-
jected with 5 3 105 (solid colums) or 2 3 105 (dotted columns) CA-6 cells
(Systemic infection) or 108 CA-6 cells (Gastrointestinal infection). Enumera-
tion of yeast cells recovered from the kidneys of mice with systemic infec-
tion or from the stomach and kidneys of mice with gastrointestinal infec-
tion was performed at different days after infection. In the gastrointestinal
infection, yeast cell counts in the kidneys were performed 4 d after intra-
venous reinfection with 5 3 106 CA-6. Cumulative data from two exper-
iments (mean 6 SE, four to six animals per group). Vertical bars, upper
limit of the standard error; *, no viable yeast units found. For each CFU
value, P , 0.05 (Student’s t test, IL-42/2 versus IL-41/1 mice).
Table 2. Candidacidal Activity and NO2
2 Production by Macrophages and Neutrophils from IL-42/2 and IL-41/1 Mice Infected with
C. albicans
Cells* Infection
Candidacidal activity† NO2
2§
IL-42/2 IL-41/1 IL-42/2 IL-41/1
%%m g/ml mg/ml
Macrophages None 51 6 4 33 6 4 1.4 6 0.5 2.6 6 1.1
CA-6 53 6 5 20 6 3 7.1 6 1.1 3.8 6 2.0
Neutrophils None 68 6 6 60 6 5 10.2 6 3.1 9.0 6 3.1
CA-6 68 6 5 14 6 2 10.6 6 2.5 11.2 6 3.2
*Macrophages were from the spleens and neutrophils from the peritoneal cavity of mice uninfected or infected with 5 3 105 CA-6 cells 3 d before.
†Macrophages and neutrophils were incubated with C. albicans at a cell/cell ratio of 5:1 for 4 and 1 h, respectively, before evaluation of Candida
growth inhibition activity.
§Nitrate determination in supernatants from cells cultured as in † was assessed by a standard Griess reaction, as detailed in Materials and Methods.311 Mencacci et al.
from IL-42/2 mice. Interestingly, the candidacidal activity
of macrophages, and lesser that of neutrophils, appeared to
be higher in uninfected IL-42/2 mice as opposed to wild-
type mice. Likewise, production of NO occurred success-
fully in IL-4–deficient mice, and to a lesser extent in wild-
type mice. Moreover, the number of peripheral white
blood cells did not differ between IL-42/2 and IL-41/1 un-
infected mice and increased comparably upon infection
(data not shown). Therefore, these data suggest that a suc-
cessful innate antifungal immune response occurs in IL-42/2
mice upon infection.
Susceptibility of IL-42/2 Mice to Candidiasis Is Associated
with Impaired Development of Antifungal CD41 Th1 Responses.
IFN-g is a potent activator of antifungal effector functions
of phagocytic cells (31, 32) and is produced by a variety of
cells, including NK and CD41 Th1s (33). Therefore, we
assessed the level of IFN-g production in cultures of un-
fractionated or purified CD41 T splenocytes obtained from
mice infected with 5 3 105 CA-6 cells, soon after infec-
tion. We also extended the analysis to IL-2, IL-4, and IL-
10 production, as resistance and susceptibility to C. albicans
is associated with preferential expansion of cells producing
Th1 and Th2 cytokines, respectively (1, 2). We found that
production of IFN-g by mitogen-stimulated splenocytes
was higher in IL-42/2 than 1/1 mice, either uninfected or
at 3 d after infection, at a time when no IL-4 or minimal
IL-10 were detected in the former mice compared to wild-
type mice (Fig. 2). On assaying cytokine levels produced
by antigen-stimulated CD41 splenocytes, a similar pattern
of Th1 cytokine production was observed in IL-42/2 and
1/1 mice, in that minimal or no IFN-g and IL-2 were pro-
duced. As expected, IL-4 and IL-10 productions were in-
creased in infected wild-type mice, as opposed to no (IL-4)
or minimal (IL-10) detection in mutant mice (Fig. 2).
Therefore, these data indicated that the early sustained pro-
duction of IFN-g in IL-42/2 mice was derived from cells
other than CD41 Th1 lymphocytes.
To investigate whether CD41 Th1 development may
occur in IL-4–deficient mice, we measured cytokine pro-
duction in culture supernatants of purified CD41 spleno-
cytes from IL-4–deficient mice infected under conditions
that would otherwise result in the activation of protective
CD41 Th1s. For this purpose, cytokine production by
splenic CD41 T cells was assessed in mice reinfected with
virulent CA-6, 14 d after the primary intravenous chal-
lenge with PCA-2 or after the primary intragastic challenge
with CA-6. The results showed (Fig. 3) that production of
IFN-g and IL-2 were elevated, as expected, in IL-41/1
mice either surviving reinfection or showing increased re-
sistance to it (Table 1). In contrast, minimal production of
both cytokines was observed in IL-4 mutant mice, suc-
cumbing to reinfection. We also assessed levels of IFN-g
gene expression in CD41 T cells from both types of mice
by competitive PCR. IL-42/2 and IL-41/1 mice were in-
jected with PCA-2 cells and assessed for IFN-g gene ex-
pression 3 d after reinfection with CA-6 cells. The results
showed a three- to fourfold increase in the IFN-g message
in CD41 cells from wild-type as compared to mutant mice
(Fig. 4). Interestingly, treatment with exogenous IL-4 re-
stored IFN-g gene expression to a level comparable to that
observed in wild-type–resistant mice.
IL-12 Production, but Not IL-12 Responsiveness, Is Impaired
in IL-4–deficient Mice Infected with C. albicans. Because IL-12 is
both required and prognostic for Th1 development in mice
with candidiasis (9, 10), we evaluated whether the failure of
IL-4–deficient mice to default to the Th1 pathway was as-
Figure 2. Cytokine production in IL-42/2 (solid columns) and IL-41/1
(dotted columns) mice infected with C. albicans. Total spleen cells (A) and
purified CD41 T splenocytes (B), obtained from uninfected mice (0) or 3 d
after intravenous challenge with 5 3 105 CA-6 cells, were mitogen or an-
tigen stimulated in vitro, respectively, for 48 h. Cytokine levels were de-
termined by means of cytokine-specific ELISA. *, Cytokine levels below
the detection limit of the assay, as indicated on the y-axis.
Figure 3. Production of IFN-g
and IL-2 in IL-42/2 ( solid col-
umns) and IL-41/1 ( dotted col-
umns) mice infected with 106
PCA-2 cells intravenously (Sys-
temic infection) or 108 CA-6 intra-
gastrically (Gastrointestinal infec-
tion). Purified CD41 T
splenocytes were obtained at 4 d
after reinfection with 5 3 105
CA-6 cells, 14 d after primary
infection. Cells were cultured in
the presence of Candida antigen
and macrophages as accessory
cells, as described in Materials and
Methods. Cytokine levels in un-
stimulated cultures were below
the detection limit of the assay,
as indicated on the y-axis.312 Anticandidal Th Responses in IL-42/2 Mice
sociated with a defective production of IL-12. We have re-
cently shown that neutrophils, more than macrophages, are
important sources of IL-12 in vivo in C. albicans infection
(25, 26). Therefore, we looked for IL-12 gene expression
in both neutrophils and macrophages from either type of
mouse after PCA-2 infection. We found that IL-12p40
message, while present in both neutrophils and macro-
phages from either type of mouse soon after infection (data
not shown), could not be detected in IL-4–deficient mice
later in infection unless mice were treated with IL-4 (Fig.
5). The message also disappeared in IL-41/1 mice upon IL-4
neutralization, a finding in line with previous data (9). We
also measured IL-12 responsiveness in both types of mice,
by assessing levels of IL-12Rb1 and IL-12Rb2 expression, as
it has recently been demonstrated that loss of IL-12 respon-
siveness, due to a selective loss of IL-12Rb2 subunit ex-
pression, represents an early step in the commitment of T
cells to the Th2 pathway (34, 35). We found that expres-
sion of the IL-12Rb1 subunit gene was similar in either
type of uninfected mice and was not modified upon C. al-
bicans infection. For the IL-12Rb2 subunit, expression was
induced by infection and was continuously present in ei-
ther type of mouse (Fig. 5). Therefore, these data suggest
that IL-12 production, but not IL-12 responsiveness, was
impaired in IL-4–deficient mice infected with C. albicans.
To verify whether IL-12 deficiency could be responsible
for the inability of IL-4–deficient mice to mount a protec-
tive CD41 Th1 response, an obvious approach would have
been to supply mice with exogenous IL-12. However, due
to an adverse effect on neutrophils (11), administration of
exogenous IL-12 to mice with candidiasis does not have a
beneficial effect (9, 11). Nevertheless, the finding that in
vitro exposure to IL-12 greatly increased production of
IFN-g by CD41 T cells from IL-42/2 mice cultured with
Candida Ag and accessory cells (data not shown), indicated
that the defective production of IL-12 may be a limiting
factor in the induction of CD41 Th1 responses in IL-42/2
deficient mice.
IL-4 Induces IL-12 Production in Response to C. albicans.
To assess whether IL-4 would directly induce production
of IL-12 in mice with candidiasis, we evaluated the effect
of IL-4 priming on the ability of neutrophils and macro-
phages to release immunomodulating cytokines, including
IL-12. Elicited peritoneal neutrophils and macrophages
from IL-4–deficient mice were exposed in vitro to IL-4
before assessing cytokine levels produced in response to
yeast cells. The results showed that priming with IL-4
greatly increased the ability of neutrophils, but not of mac-
rophages, to release IL-12, with the levels of production
being similar to those observed in IL-41/1 mice (Fig. 6 A).
Interestingly, priming with IL-4 increased IL-6 production
from both types of cells. The potent stimulatory effect on
Figure 4. Relative levels of IFN-g mRNA in CD41 T cells from naive
or C. albicans–infected IL-41/1 and IL-42/2 mice. Mice were infected
with 106 PCA-2 intravenously and reinfected with 106 virulent CA-6 14 d
later. Cells were purified from spleens at 3 d after reinfection. *, Mice
were infected as above and treated with rIL-4 (3 mg/each injection) on
days 6, 8, 10, and 12 after PCA-2 infection. Semiquantitative competitive
PCR was performed as described by Reiner et al. (30). Photographs are
shown of ethidium bromide–stained gels of representative PCR reactions
using HPRT– and IFN-g–specific primers in the presence of serial five-
fold dilutions of the experimental sample and a fixed concentration of the
competitor, as described in Materials and Methods. The upper band was
due to amplification of the competitor construct and the lower band was
due to amplification of cDNA. The point of equivalence in intensity be-
tween the competitor and cDNA indicates the relative concentration of
mRNA. The relative concentration of HPRT was used to control differ-
ences in mRNA concentration and efficiency of cDNA synthesis.
Figure 5. Expression of IL-12 and IL-12R genes in IL-42/2 and IL-41/1
mice infected with C. albicans. Purified splenic macrophages, peritoneal
neutrophils, and CD41 splenocytes were obtained from uninfected mice
(lane 1) or from PCA-2–infected mice 3 d after reinfection with 106 CA-
6 cells (lane 2). PCA-2–infected mice were treated with rIL-4 (IL-42/2
mice) or with anti-IL–4 mAb (IL-41/1) before reinfection (lane 3), as de-
scribed in Table 3. Cytokine gene expression was assessed by RT-PCR.
N, no DNA added to the amplification mix during PCR; C, HPRT- or
cytokine-specific controls.313 Mencacci et al.
neutrophils appeared to be due to a direct effect of IL-4 on
these cells. In fact, expression of IL-4R in response to Can-
dida cells was induced by priming with IL-4 as opposed to
what observed in macrophages, whose IL-4R expression
appeared to be decreased upon IL-4 priming (Fig. 6 B).
The same potentiating effect was observed by adding IL-4
and yeast cells simultaneously (data not shown). These data
suggest that IL-4 may be required for an optimal produc-
tion of IL-12 by neutrophils in mice with candidiasis.
Late Treatment with Exogenous IL-4 Increased Th1-mediated
Anticandidal Resistance in IL-4–deficient Mice. We have al-
ready shown that IL-4 production late in infection is asso-
ciated with the detection of protective CD41 Th1s and is
positively regulated by IL-12 (13). Neutralization, but not
administration, of IL-4 late in the course of infection alters
an already established CD41 Th1 response to C. albicans
(13). Here we show that treatment with IL-4 early in the
course of infection greatly exacerbated the infection in
both IL-42/2 and 1/1 mice (data not shown), as expected
(12). Late treatment with IL-4 greatly increased resistance
of PCA-2–infected mutant mice to reinfection, as revealed
by increased survival, decreased fungal growth in the kid-
Figure 6. Effect of IL-4 on cy-
tokine production (A) and IL-
4R expression (B) on neutrophils
and macrophages from IL-42/2
(solid columns) or IL-41/1 (dotted
columns) mice. Elicited peritoneal
neutrophils or macrophages were
cultured in vitro with IFN-g 1
LPS or C. albicans cells. Priming
with IL-4 was done by adding
250 U/ml of rIL-4 8 h before C.
albicans ( striped columns, A; and
lane  2,  B). After 24 h incubation,
supernatants were assayed for cy-
tokine contents and cells for IL-
4R expression by RT-PCR. *,
Cytokine levels below the detec-
tion limit of the assay, as indi-
cated on the y-axis. Lane 1, C.
albicans alone. N, No DNA
added to the amplification mix
during PCR; C, HPRT- or cy-
tokine-specific controls.
Table 3. Late IL-4 Administration Restores Resistance and CD41 Th1 Cytokine Production in C. albicans–infected IL-42/2 Mice
Mice*
Treatment†
MST CFU 3 103§
Cytokine productioni
rIL-4 mAb Anti-Ly6G mAb Anti–IL-4 IFN-g (ng/ml) IL-2 (U/ml)
IL-42/2 22 2 7 1,220 6 89 ,0.1 64 6 5
IL-42/2 12 227¶ 360 6 65¶ 78 6 10 156 6 14
IL-42/2 21 2 4 3,530 6 148 19 6 3 50 6 8
IL-42/2 11 211¶ 1,047 6 111¶ 48 6 8 144 6 28
IL-41/1 22 2 . 60 225 6 81 81 6 13 187 6 17
IL-41/1 12 2 . 60 304 6 102 119 6 12 148 6 24
IL-41/1 22 121** 581 6 94 24 6 3 89 6 9
IL-41/1 21 2 5 2,824 6 177 29 6 4 66 6 10
IL-41/1 11 214¶ 811 6 79¶ 54 6 2 104 6 15
*Mice were infected intravenously with 106 PCA-2 and reinfected 14 d later with 106 CA-6. 
†Treatment with rIL-4 (12 mg total dose, given together with the 11B11 anti–IL-4 mAb) or with the 11B11 mAb (2 mg, total dose) was done every
other day from 6 to 12 d after primary PCA-2 infection. The neutrophil-depleting mAb (anti-Ly6G) was given intraperitoneally (100 mg/mouse) 2 d
before reinfection. Neutrophil-depleted mice were treated twice with rIL-4 (as above) 2 and 1 d before reinfection.
§Colony forming units in the kidneys at 3 d after reinfection.
iCytokine contents of supernatants of CD41 T cells from spleens of 3-d reinfected mice cultured in vitro with C. albicans antigen and accessory mac-
rophages.
¶P ,0.05 Student’s t test (rIL-4–treated versus untreated mice).
**P ,0.05 Student’s t test (anti–IL-4 mAb-treated versus untreated IL-41/1 mice).314 Anticandidal Th Responses in IL-42/2 Mice
neys, and increased production of IFN-g and IL-2 by
CD41 T cells. In contrast, IL-4 neutralization reduced re-
sistance of wild-type mice (Table 3). To assess whether
mechanisms other than regulation of IL-12 produced by
neutrophils may contribute to the ability of IL-4 to sustain
Th1-dependent anticandidal immunity, IL-4 was adminis-
tered to IL-42/2 and IL-41/1 mice depleted of neutrophils.
To this purpose, groups of mice with primary infection
were injected with the anti-Ly6G mAb 2 d before reinfec-
tion and treated with exogenous IL-4. Depletion of neu-
trophils decreased resistance to reinfection in both types of
mice, as expected (25). However, exogenous IL-4 partially
restored resistance of neutrophil-depleted mice, as indi-
cated by the increased survival, decreased fungal growth,
and increased production of IFN-g and IL-2. Interestingly, the
effects of IL-4 administration were similar to those observed in
mice with primary infection and treated with IL-12–neu-
tralizing Ab before reinfection (data not shown). All to-
gether these data indicate that exogenous IL-4 can increase
Th1-mediated anticandidal resistance in IL-4–deficient mice,
and that mechanisms other than those regulating IL-12
production by neutrophils may significantly contribute to
this effect.
Discussion
The results of the present study reveal a novel, previously
unappreciated, role for IL-4 in vivo in mice with C. albi-
cans infection, in which endogenous IL-4 is required for
the induction of protective antifungal CD41 Th1 re-
sponses. Previous studies demonstrating the beneficial (4, 5)
or detrimental (12) effect of early IL-4 neutralization or ad-
ministration, respectively, in mice with candidiasis led us to
conclude that the occurrence of Th1 or Th2 responses pos-
itively correlated with the presence or the absence of IL-4.
However, the subsequent finding that peak production of
IL-4 occurred in mice with candidiasis concomitantly with
the expression of protective, Th1-mediated resistance, and
that depletion but not administration of IL-4 late in infec-
tion decreased resistance and production of IFN-g and IL-
12, suggested that IL-4 may have a positive effect in C. al-
bicans infection, at least in the late stage (13). In the present
study, we found that IL-4–deficient mice, while having an
impaired Th2 response, did not default to the Th1 path-
way, thus becoming highly susceptible in the late stage of
C. albicans infection. Susceptibility to infection was not as-
sociated with signs of Th2 activation, such as production of
IL-10 and high levels of circulating specific IgE (data not
shown). Also, the message of IL-13 was only transiently in-
duced in IL-42/2 and IL-41/1 mice upon infection (data
not shown), thus ruling out the possibility that IL-13,
which signals through the IL-4Ra chain (36), may com-
pensate for IL-4 deficiency. Therefore, IL-4 is the most
important cytokine in the induction of CD41 Th2 re-
sponses in candidiasis. A similar finding was observed in IL-4–
deficient mice infected with a variety of pathogens, which
have impaired Th2 responses but enhanced (23, 37–41) or
not (14, 42) Th1 responses. We found that production of
IFN-g by CD41 Th splenocytes was reduced in IL-42/2
mice compared to wild-type mice in response to virulent
C. albicans, but also in experimental conditions of infection
that otherwise result in the induction of CD41 Th1. De-
fective activation of CD41 Th1 was not associated with de-
fective IL-12 responsiveness, as the expression of IL-12Rb2s
on these cells was not different from that observed in wild-
type mice mounting a CD41 Th1 response. Therefore,
these data indicate that the unimpaired expression of IL-12b2
on CD41 cells, due to the lack of inhibitory IL-4 (34, 35),
may not correlate with the functional activation of CD41
Th1s in murine candidiasis.
The results obtained in the present study clearly evidence
a two-stage control of infection in mice with C. albicans in-
fection. In the early stage, an innate immune response, if
unopposed, may successfully control infectivity in the ab-
sence of a supportive CD41 Th1 response, as observed in
IL-4–deficient mice exposed to low or moderate yeast in-
ocula or with gastrointestinal infection. In this condition,
IFN-g derived from a non–T cell compartment, presum-
ably NK cells (33), represents one possible activator of anti-
fungal effector cells (31, 32). However, in the late stage of
infection, IL-12 and CD41 Th1s producing IFN-g are
required to cope successfully with the pathogen. Indeed,
IL-42/2 mice failed to develop protective CD41 Th1 re-
sponses, as observed upon intravenous or mucosal immuni-
zation, thus becoming susceptible to infection at the late
stage. Although IL-4–deficient mice appeared to be resis-
tant to mucosal infection, the data of the present paper do
not seem to suggest a possible late exacerbation of the in-
fection, a finding compatible with the notion that IL-4 may
mediate both protection (43) and pathology (44) at the
mucosal level.
IL-4 appears to be required for the optimal occurrence
of both innate and adaptive immune responses. Fungal
elimination in IL-42/2 BALB/c mice was not as efficient as
in genetically resistant similarly infected mice (our unpub-
lished observation), thus suggesting that IL-4 may exert a
positive effect on the antifungal effector function of phago-
cytic cells. In this regard, IL-4 has been reported to en-
hance murine macrophage mannose receptor activity (45)
and to stimulate phagocytosis and killing of yeast cells by
macrophages (46) and neutrophils (47). Both types of cells
express surface receptors for IL-4 (48, 49). We have previ-
ously reported that IL-4 inhibits candidacidal activity and
NO release by macrophages (27), and in the present study
we found that both activities were unimpaired in IL-4–
deficient mice. It is likely that IL-4 may both positively and
negatively affect the antifungal effector functions of phago-
cytic cells, the net result being dependent on the dose and
time of infection, as observed in leishmaniasis (50).
Whatever the effect of IL-4 on the antifungal effector
functions of phagocytic cells, in this study we found that
IL-4 efficiently primed neutrophils for IL-12 production in
response to the fungus. The effect was associated with the
induction of IL-4R on these cells. That IL-4 can prime for
IL-12 production has already been observed (51, 52). In
human mononuclear cells (51) the positive effect of IL-4315 Mencacci et al.
priming on IL-12 production appeared to be due to IL-10
inhibition. Because neutrophils produce IL-12 and IL-10
in response to C. albicans (25, 26), this mechanism could be
at work in our system. Interestingly, priming with IL-4 also
resulted in the release of high levels of IL-6, which is
known to regulate IL-4 receptors on murine myeloid pro-
genitor cells (53). Therefore, it appears that a positive am-
plification loop exists between IL-6 and IL-4 at the level of
neutrophil response, which may be one possible mecha-
nism underlying the beneficial effect of IL-6 in mice with
candidiasis (54).
The defective production of IL-12 may likely contribute
to the impairment of CD41 Th1 development in IL-4–defi-
cient mice with C. albicans infection, as it has been shown
that exposure to IL-12 restores IFN-g production in CD41
T cells from IL-42/2 mice (22). However, the ability of IL-4
to increase IFN-g and IL-2 production in the relative ab-
sence of neutrophils also suggests a possible direct effect of
IL-4 on effector Th1s. Elegant studies by Flavell et al. have
recently shown that developing Th1 lineage cells produce
low levels of IL-4 as they differentiate into Th1 effectors
(20, 21), thus implying that endogenous IL-4 could play an
as yet not completely defined physiologic role in modulat-
ing Th1 effectors (20–22). Further studies will elucidate the
important role of endogenous IL-4 in CD41 Th1 differen-
tiation and maintenance in C. albicans infection.
One interesting and still partially unresolved issue raised
by our studies is where does IL-4 come from and which
yeast/host factors regulate its production in mice with C.
albicans infection. Evidence indicates that TCR-a/b1 cells,
with an activated phenotype and a biased Vb receptor ex-
pression, are the early producers of IL-4 in infected mice
(55). The interaction between Candida cells and/or fungal
products with cells producing IL-4 appears to occur
through a superantigen-like mediated mechanism (55, 56).
Whether the late peak production of IL-4 occurring in
mice with candidiasis also occurs in recognition of superan-
tigen-like molecules produced by fungal processing or fun-
gal growth polymorphism remains an interesting possibil-
ity. Late peak production of IL-4 has also been observed in
resistant mice infected with Leishmania major, and appears
to be an essential component of the immune response to
this parasite (57, 58).
In conclusion, this study provides several novel features
of the immune response to C. albicans, including a physio-
logic role for IL-4 in the induction and maintenance of
IL-12–dependent protective cell-mediated immunity.
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